Company profile: F2G
1.1 - Company Overview
Company description
- Provider of novel antifungal drug discovery and development, advancing patented compounds and technologies to treat life-threatening fungal diseases. Founded on proprietary genomics technology (MycoBank) that identifies essential gene targets in fungi.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to F2G
Altesa BioSciences
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical research and development focused on accelerating the development of new treatments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Altesa BioSciences company profile →
Spectral Medical
HQ: Canada
Website
- Description: Provider of therapies and diagnostics for septic shock and sepsis risk, including Toraymyxin (PMX) hemoperfusion to remove endotoxin and the Endotoxin Activity Assay (EAA). Conducts the Tigris Phase 3 study of PMX with standard care. Also offers the DIMI hemodialysis system for continuous renal replacement therapy, licensed for hospitals, clinics, and homes in Canada and the USA, and the SAMI device for continuous renal replacement therapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Spectral Medical company profile →
Novan
HQ: United States
Website
- Description: Provider of nitric oxide-based therapeutics, developing deliverable nitric oxide via its NITRICIL platform and offering ZELSUVMI, a topical gel (10.3% berdazimer) approved by the U.S. FDA for treating molluscum contagiosum.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Novan company profile →
Cocrystal Pharma
HQ: United States
Website
- Description: Provider of antiviral therapeutics and candidates, including oral and inhaled PB2 inhibitor CC-42344 for Influenza A (oral: Phase 1 completed, Phase 2 ongoing; inhaled: Phase 1 and 2 completed); preclinical replication inhibitors for Influenza A/B; oral pan-viral protease inhibitor CDI-988 targeting coronavirus and norovirus (preclinical completed, Phase 1 ongoing); and discovery/preclinical pan-viral and norovirus replication inhibitors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cocrystal Pharma company profile →
Ibis Biosciences
HQ: United States
Website
- Description: Provider of products for the identification and characterization of infectious agents, including the Ibis T5000 Biosensor System, a hardware platform that identifies biological organisms such as bacteria, viruses, fungi and protozoa and provides information on drug resistance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ibis Biosciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for F2G
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to F2G
2.2 - Growth funds investing in similar companies to F2G
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for F2G
4.2 - Public trading comparable groups for F2G
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →